Basit öğe kaydını göster

Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.

dc.contributor.authorYagci, Munci
dc.contributor.authorBEKSAÇ, MERAL
dc.contributor.authorAydin, Yildiz
dc.contributor.authorGÖKER, HAKAN
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorTuglular, Tulin
dc.contributor.authorVURAL, FİLİZ
dc.contributor.authorALACACIOĞLU, İNCİ
dc.contributor.authorAytan, Pelin
dc.contributor.authorGoksoy, Hasan Sami
dc.contributor.authorGulbas, Zafer
dc.contributor.authorGunes, Ahmet Kursad
dc.contributor.authorGÜRKAN, EMEL
dc.contributor.authorHacioglu, Sibel Kabukcu
dc.contributor.authorKarti, Suleyman Sami
dc.contributor.authorKAYNAR, LEYLAGÜL
dc.contributor.authorOzdogu, Hakan
dc.contributor.authorPAYDAŞ, SEMRA
dc.contributor.authorSolmaz, Soner
dc.contributor.authorSÖNMEZ, MEHMET
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorYILDIRIM, Rahşan
dc.contributor.authorİLHAN, OSMAN
dc.contributor.authorBesisik, Sevgi
dc.date.accessioned2021-03-02T17:30:24Z
dc.date.available2021-03-02T17:30:24Z
dc.date.issued2020
dc.identifier.citationBEKSAÇ M., Aydin Y., GÖKER H., Turgut M., Besisik S., Cagirgan S., Tuglular T., VURAL F., Yagci M., ALACACIOĞLU İ., et al., "Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.", Clinical lymphoma, myeloma & leukemia, cilt.20, sa.8, 2020
dc.identifier.issn2152-2650
dc.identifier.otherav_2aabaa90-d582-4926-acf4-7d4402c685cb
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3887
dc.identifier.urihttps://doi.org/10.1016/j.clml.2020.02.017
dc.description.abstractThe present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.
dc.language.isoeng
dc.subjectHEMATOLOJİ
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectHematoloji
dc.subjectOnkoloji
dc.titleEarly Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
dc.typeMakale
dc.relation.journalClinical lymphoma, myeloma & leukemia
dc.contributor.departmentAnkara Üniversitesi , ,
dc.identifier.volume20
dc.identifier.issue8
dc.contributor.firstauthorID2285663


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster